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1.1   ABSTRACT  
 
Background: Thyroid dysfunction is one of the most common endocrine disorder. Thyroid 
dysfunction affects the female reproductive system and can be manifested by menstrual 
irregularities, pregnancy loss and infertility. Unexplained infertility has an incidence of 10 to 
15 % worldwide.  
Aim: The general objective of this thesis was to explore the importance of thyroid function 
for reproduction  
Material and method: Serum levels of thyroid stimulating hormone (TSH) were compared 
in three groups of women in early pregnancy, one high-risk group (n = 88), one low-risk 
group (n = 511) and a general screening group (n = 699). Serum levels of TSH, free thyroxine 
(fT4) and thyroid peroxidases antibodies (TPO Ab) in fertile women (n = 67) were compared 
to women with unexplained infertility (n = 147). By using immunohistochemistry, the protein 
staining of thyroid hormone receptors (TRα1 and TRβ1), TSH receptor (TSH R), mono 
carboxylate transporter-8 (MCT8), and type 2 iodothyronine deiodinases (DIO2)] in 
endometrial biopsies were compared between fertile women (n = 19) and women with 
unexplained infertility (n = 28). Thyroid related proteins in different part of Fallopian tube 
during the menstrual cycle in fertile women (n=13) were analyzed. Additionally, embryo 
development until day 6, in 38 human embryos cultured in standard media with T4 added 
were compared to development of 36 embryos cultured in standard media. 
Results: The incidence of subclinical hypothyroidism and hypothyroidism was almost the 
same in all three study groups (almost 10 %). Hypothyroid women on levothyroxine (LT4) 
supplementation had in almost 50 % of cases an inadequate treatment. Women with 
unexplained infertility had significantly higher serum level of fT4, and lower protein staining 
of TRα1 and MCT8, in the endometrium. Supplementation of thyroid hormone in vitro 
culture media improved the blastocyst development. Additionally, we showed thyroid related 
proteins in the Fallopian tube. 
Conclusion: It can be concluded that a general screening for thyroid dysfunction during early 
pregnancy, by use of TSH levels, is optimal. Furthermore, the imbalance in the thyroid 
system in women with unexplained infertility highlights the importance of thyroid hormone 
for female fertility. The improvement of blastocyst development by adding thyroid hormone 
in early embryo cultures and the presence of proteins related to thyroid in Fallopian tubes 
suggest involvement of thyroid hormone in early embryo development.  
 
Keywords: TSH screening, early pregnancy, thyroid hormone, endometrium, Fallopian tube, 
embryo culture, unexplained infertility, MCT8, DIO2, thyroid hormone receptor, TSH 
receptor 
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2.   INTRODUCTION  
2.1   THYROID 
2.1.1   Thyroid hormones 
           Thyroid hormones (TH), thyroxine (T4) and 3,3’, 5-trijod-L-tyronin (T3), are secreted 
from and stored in the thyroid gland. Thyroid hormones regulate energy homeostasis, cell 
proliferation, and carbohydrate-, fat- and protein metabolism. 
  
2.1.2   The hypothalamic and the pituitary regulation of thyroid 
hormone secretion 
 
The production of THs is mainly regulated by hypothalamic – pituitary – thyroid axis [1]. 
Thyroid stimulating hormone (TSH) stimulates the production of TH in response to thyroid 
releasing hormone, produced by the hypothalamus. Thyroid releasing hormone (TRH) is 
transported to the pituitary via the hypothalamic hypophyseal portal system. TSH and TRH 
are regulated by negative feedback by T3 and T4. Furthermore, thyroid hormone levels are 
under influence of other hormones such as glucocorticoids, somatostatin, dopamine, 
prolactin, estrogen and growth hormones (Figure 1). 
 
 
Figure  1.  The  hypothalamic-­pituitary-­thyroid  axis.  
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Dopamin(-)
Prolactin(-)
GH(-)
Estrogen(+)
Glucocorticoids(-)
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2.1.3   Thyroid stimulating hormone, TSH and TSH receptor 
  
                      TSH is a heterodimeric glycoprotein hormone that shares the α-subunit with other 
glycoprotein hormones, such as human chorionic gonadotrophin (hCG), follicle stimulating 
hormone (FSH) and luteinizing hormone (LH) but it has an unique β-subunit. TSH exerts its 
effect by binding to the TSH-receptor (TSH R), which is located in the cell membrane of 
thyroid follicular cells. TSH R is a member of the G-protein associated receptor family, 
similar to the hCG and LH receptors [2, 3]. TSH R expression has been shown in thyroidal 
tissue and also in extra-thyroidal tissues such as adipose tissue, testes, ovaries and 
endometrium [4, 5].  
 
2.1.4   Thyroid hormone secretion  
  
                    Follicular epithelial cells located in the thyroid gland produce thyroid hormones, 
mainly T4. They are hydrophobic hormones that are to more than 99 % bound to proteins, 
mainly to thyroxine binding globulin (TBG). The free fractions of thyroid hormones (fT4, 
fT3), which mediate thyroid hormone action in target cells, are estimated to 0.02 % of total 
T4 and 0.30 % of total T3.  
The local enzymatic conversion of thyroid hormone in target tissues is regulated by 
iodothyronine deiodinases [6]. The majority of T3 in the circulation is derived from 
conversion of T4 by type 2 iodothyronine deiodinases (DIO2) and type 1 iodothyronine 
deiodinases (DIO1). The inactivation of T4 and T3 to reverse T3 (rT3) is mediated by type 3 
iodothyronine deiodinase (DIO3)[7].   
Cellular transport of thyroid hormone requires active transport across the plasma membrane. 
This is mediated through different members of mono carboxylate transporter (MCT) and 
organic anion transporting polypeptide (OATP) depending on target cells[8] . 
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2.1.5   Thyroid hormone receptor 
  
                    Thyroid hormones exert their biologic effect through thyroid hormone receptors (TRs), 
which act as transcription factors to regulate gene expression [9]. TRs bind to a short DNA 
sequence of target gene called thyroid response element (TRE), which leads to transcription. 
By contrast, TRs interaction with the response elements, in absence of T3 leads to 
suppression of basal transcriptional activity [10] (Figure 2). 
 
  
  
Figure  2.  The  action  of  thyroid  hormone  in  the  target  cells.  Thyroid  hormone  receptors  (TRs),  Thyroid  
response  element  (TRE),  mono  carboxylate  transporter  (MCT),  organic  anion  transporting  polypeptide  
(OATP),  type  2  iodothyronine  deiodinases  (D2)  and  type  1  iodothyronine  deiodinases  (D1).  
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Thyroid receptors are encoded by two genes, TRα and TRβ, each with three isoforms; TRα1, 
TRα2 and TRα3 and TRβ1, TRβ2 and TRβ3 [11]. Thyroid receptors are expressed in most 
tissues and they have higher affinity to T3 than T4. TRα1 is predominantly expressed in 
brain, heart and skeletal muscles. [11]. TRβ1 is widely expressed in different organs except 
testes[12] . TRα1, TRα2 and TRβ1 have been shown in endometrium[4, 5].     
 
2.2   THYROID DYSFUNCTION  
  
          Changes in serum concentration levels of TSH are the most commonly used indicator 
of thyroid dysfunction such as autoimmune thyroid dysfunction, hypothyroidism, subclinical 
hypothyroidism and hyperthyroidism.  
  
  
2.2.1   Hypothyroidism 
  
           Hypothyroidism is defined as low levels of thyroid hormone combined with elevated 
levels of TSH. Hypothyroidism can be due to low secretion of hormone from the thyroid 
gland, primary hypothyroidism, or due to low levels of TSH, that is central hypothyroidism. 
The worldwide prevalence of hypothyroidism is between 0.6 to 12 per 1000 women and 1.3 
to 4 per 1000 men [13].  
Iodine deficiency is the most common cause of hypothyroidism worldwide [14, 15]. In iodine 
sufficient countries like Sweden, the most common thyroid disorder is chronic autoimmune 
thyroiditis, usually known as Hashimoto’s thyroiditis. The diagnosis of Hashimoto’s 
thyroiditis is confirmed by the presence of anti-thyroid peroxidase antibodies (TPO-Ab)[16]. 
Hypothyroidism can also be caused by earlier treatment of Graves´ disease such as anti-
thyroid drugs, thyroidectomy or radioiodine treatment.   
Symptoms of hypothyroidism are nonspecific and vary due to the severity of the disorder. 
Dry brittle hair and nails are common in these patients who may also have symptoms of 
chilliness, fatigue, weight gain and slowing of higher mental function. Treatment of 
hypothyroidism is thyroid hormone (L-T4) substitution. 
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2.2.2     Subclinical hypothyroidism 
 
           Subclinical hypothyroidism (SCH), defined as elevated serum levels of TSH combined 
with normal thyroid hormone levels [17]. Studies performed in the United States have shown 
a prevalence of 3 to 15 % of SCH. Women with SCH may have vague or nonspecific 
symptoms or have symptoms similar to those with hypothyroidism. Women with TPO-Ab 
and elevated TSH levels are at higher risk of progressing from SCH to hypothyroidism [18, 
19]  Women with TPO-Ab are at higher risk to development postpartum thyroiditis [20, 21].  
 
2.2.3   Hyperthyroidism (thyrotoxicosis) 
 
          Hyperthyroidism is defined as elevated thyroid hormone levels combined with almost 
undetectable levels of TSH. It affects approximately 2.0 % of women and 0.2 % of men 
worldwide. The most common type of hyperthyroidism is Graves´ disease. This condition is 
due to stimulation of thyroid gland by TRAb on the thyroid follicular cells [18].   
Common symptoms of hyperthyroidism are weight loss, palpitations, tremulousness, heat 
intolerance, and anxiety. Physical findings such as tachycardia, thyroid enlargement and 
tremor are also seen. Treatment options are: anti-thyroid drugs, surgery and radioiodine 
treatment. 
 
2.3   THYROID DYSFUNCTION AND FEMALE REPRODUCTION 
 
2.3.1   Hypothyroidism  
 
          Women with hypothyroidism have low levels of sex hormone binding globulin 
(SHBG) and low levels of estrogen and testosterone [22]. Menstrual disturbances such as 
oligomenorrhea, amenorrhea and menorrhagia are common in hypothyroid women. These 
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disturbances can partly be due to TRH-induced hyperprolactinemia and thus altered pulsatile 
GnRH secretion and partly due to defect hemostasis with low levels of coagulation factors. 
[23-25]. 
 
2.3.2   Hyperthyroidism (thyrotoxicosis) 
 
          Thyrotoxicosis may lead to different symptoms ranging from normal menstrual cycles 
to menstrual irregularities such as menorrhagia, oligomenorrhea, amenorrhea, anovulation 
and reduced fertility [26, 27] . Women with Graves´ Disease have 2 to 3 times higher serum 
levels of estrogen and LH during all phases of the menstrual cycle, probably due to high 
levels of SHBG [27] . The production of testosterone and androstenedione is also increased in 
these women [28].  
 
 
2.4   THYROID AND PREGNANCY 
 
 
2.4.1   The change in thyroid hormone production during 
pregnancy 
 
          In early pregnancy an estrogen derived increase in TBG (2.5-fold higher) occurs which 
requires an increase in thyroid hormone production and a higher daily intake of iodine (250 
µg) [29-32] [33]. While the free fraction of thyroid hormone is slightly increased during the 
first trimester of pregnancy, the total serum levels of thyroid hormones are 1.5-fold higher in 
pregnant women than in non-pregnant women. The TSH levels have a transient fall during 
the first trimester of pregnancy due the thyrotrophic action of hCG [34], the lowest levels are 
seen around 10-12 weeks of gestation. In iodine sufficient areas the TSH levels will remain 
stable and similar to pre-gestational levels after the first trimester until the end of pregnancy.  
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2.4.2   Thyroid hormones and fetus 
 
           Despite incorporation of iodine late in the first trimester of pregnancy, the fetus does 
not start to secrete its own thyroid hormones until 18th to 20th weeks of pregnancy. Thus, the 
fetus is totally dependent on the trans-placental passage of maternal thyroid hormone during 
the early stages of pregnancy [35, 36]. During pregnancy, the fetus can also be affected by 
maternal thyroid receptor antibodies and anti-thyroid drugs due to trans-placental passage 
(Figure 3). 
 
Figure  3:  The  trans-­placenta  passage  of  thyroid  hormones  and  thyroid  hormone  related  factors.  
 
 
            The fetus normal growth and neurologic development is dependent on optimal levels 
of thyroid hormones. Thyroid hormones influence neurodevelopmental events, such as 
neurogenesis, myelination, dendrite proliferation and synaptogenesis [37, 38].  
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2.5   THYROID DYSFUNCTION DURING PREGNANCY  
 
 
2.5.1   Hypothyroidism/ subclinical hypothyroidism or isolated 
hypothyroxinemia  
 
        Untreated hypothyroidism has been associated with an increased risk of obstetric and 
fetal complications while this it is not the case in isolated hypothyroxinemia or SCH [39, 40] 
[41]. Hypothyroidism and SCH have been associated with adverse fetal and obstetric 
outcome such as miscarriages, preterm labor, before 32 weeks of gestation, postpartum 
hemorrhage, respiratory fetal distress, intrauterine growth retardation (IUGR) and 
neurological disorders [39, 40, 42-46]. However, there is less evidence that untreated SCH 
during pregnancy is associated with neurological disorders in the fetus [47].  
 
 
2.5.2   Hyperthyroidism   
 
           Untreated hyperthyroidism is associated with adverse outcomes of pregnancy such as 
miscarriage, preeclampsia, and preterm delivery. There is a significantly higher risk of fetal 
complications including IUGR and congenital heart failure even in euthyroid status in the 
mother, due to the presence of TRAbs. Both thyroid antibodies and anti-thyroid drugs have 
the ability to pass through placenta [48]. Pregnancy with positive TRAbs, require careful 
monitoring of thyroid status and TRAbs and controls of the fetus (ultrasonography) during 
pregnancy. The change of the immune system during pregnancy leads to remission in 
Graves´ disease like many other autoimmune diseases with a risk for a postpartum relapsing 
[49].  
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2.5.3   Gestational thyrotoxicosis 
   
            The production of fT4 increases during pregnancy due to secretion of hCG, with a 
peak during the 10th to12th weeks of gestation. hCG is a glycoprotein, which shares the alpha 
unite with TSH and can act as a TSH agonist. This leads to suppression of TSH and transient 
hyperthyroxinemia in the first trimester of normal pregnancy as well as multiple pregnancy 
and may cause hyperemesis gravidarum [50-52].  
 
 
2.5.4   Postpartum thyroid dysfunction  
 
            Postpartum thyroiditis is a destructive autoimmune disease with a prevalence of 5 to 9 
% and usually occurs within the first year after delivery. Women with diabetes mellitus type 
1 have a threefold higher risk of developing postpartum thyroiditis. Women with positive 
TPO antibodies during early pregnancy have 50 % risk of developing postpartum thyroiditis 
and an increased risk of developing a permanent hypothyroidism [17, 53, 54]  
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3.   ENDOMETRIUM  AND  FALLOPIAN  TUBE  
 
3.1   ENDOMETRIUM  
 
        The uterine wall consists of three layers; a thin lining, endometrium, a muscular layer 
myometrium and serosa. The endometrium, which is the innermost portion of uterus, can be 
divided into two layers, the upper functional layer where the implantation of blastocyst takes 
place and the basal layer. From the basal layer, the monthly regeneration of endometrium 
takes place. Histologically, the endometrium contains a layer of columnar epithelium on the 
surface and in the glands and a layer of stromal connective tissue. The stromal connective 
tissue contains fibroblasts, endothelial cells and leukocytes.  
 
3.1.1    Endometrial differentiation during menstrual cycle  
 
         During the menstrual cycle the monthly preparation of the endometrium for 
implantation occurs. Differentiation of the endometrium during the menstrual cycle is a 
reflection of the hormones produced by the ovary [55]. The main hormones from the ovary 
are estrogens (E) and progesterones (P). A feedback system, consisting of hormones secreted 
from the hypothalamus, pituitary and ovaries regulates the menstrual cycle [56]. The 
menstrual cycle can be divided into three phases due to endometrial changes: one 
degenerative phase called menstrual phase, one proliferative phase which corresponds to the 
ovarian follicular phase, and one secretory phase, which corresponds to the ovarian luteal 
phase.  
The first days of the menstrual cycle is initiated by the presence of a bleeding, due to 
degeneration and expulsion of the endometrium. The follicular phase is characterized by 
growing follicles and secretion of estrogen. During this phase, selection of a dominant follicle 
occurs [57, 58]. The increasing estrogen levels during the follicular phase stimulate 
proliferation of the endometrium, which becomes thicker and with increasing number of 
glands. 
After the LH surge in the middle of the cycle, the dominant follicle ruptures and the oocyte is 
released [59]. The residual follicle rearranges to form a corpus luteum which secrets both 
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estrogens and progesterones [56]. During the luteal phase, the endometrium is prepared for 
implantation of a blastocyst. In absence of pregnancy, degeneration of the endometrium 
starts. After two weeks the corpus luteum forms corpus albicans. The secretion of estrogens 
and progesterones has dropped to low levels, which leads to degeneration of the 
endometrium. 
 
 
         
Figure 6: The menstruation cycle and its related hormones: Gonadotropic hormones; Follicle 
stimulating hormone (FSH), Luteinizing hormone (LH). Gonadal hormones estrogen and progesterone.  
 
3.2   FALLOPIAN TUBE  
 
        The Fallopian tubes, are divided into four parts from the uterine horns to the ovaries; the 
interstitial part which transverses the uterine musculature, the isthmus, the ampulla which 
represents the major lateral part of tubes, where the fertilization of ovum takes place and the 
infundibulum with its fimbriae. The Fallopian tube wall consists of four distinct layers; 
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serosa, subserosa, lamina propria and mucosa. The mucosa is a single layer of cells with cilia 
throughout the tubes. 
 
4.   IMPLANTATION  
 
        Implantation requires fertilization of a haploid oocyte by a haploid sperm in the 
Fallopian tube, the development of the early embryo to blastocyst during its transport in the 
Fallopian tube and finally implantation of the embryo into the endometrium [60, 61]. It also 
includes hatching of the blastocyst at the end of the first week of embryonic development, to 
the formation of primitive placenta at the mid second week of embryonic development.  
 
5.   INFERTILITY  
 
          Infertility has been defined as the inability to conceive after one year or more of regular 
intercourses without contraception. The monthly fecundity rate in fertile couples has been 
estimated to 10 to 15 % [62]. The American Society for Reproductive Medicine (ASRM) and 
the World Health organization (WHO) considers infertility as a reproductive disease and has 
recommended investigation and treatment after one year for women below the age of 35 and 
six months for women over the age of 35. The etiology of infertility can be related to male or 
female factors or combinations of both. In more than 10 % of cases the etiology of infertility 
is unexplained [63, 64]. The female causes of infertility include age dependent factors, luteal 
phase defects, genetic abnormalities, anatomical abnormalities, post inflammatory factors, 
peritoneal factors, endometrioses and polycystic ovary syndrome.  
Assisted reproductive technology (ART) involves methods used for treatment of couples with 
infertility such as, clomiphene citrate and intrauterine insemination, gonadotropin treatment 
and intrauterine insemination, in vitro fertilization (IVF) and intracytoplasmic sperm injection 
(ICSI). Despite optimization of ART, all attempts to treat are not successful. A better 
understanding of the mechanisms involved in implantation will be beneficial for infertility 
treatment including increased chance of spontaneous pregnancy.  
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6.   AIM  OF  THE  STUDIES  
 
6.1   GENERAL AIM  
 
         The overall aim of the studies was to explore the influence of thyroid hormone system 
on female reproduction. 
 
 
6.2   SPECIFIC AIMS 
 
 -To detect incidence of subclinical hypothyroidism and hypothyroidism in a representative 
group of Swedish women in early pregnancy. 
- To compare serum and endometrial levels of thyroid related factors in fertile women and 
women with unexplained infertility.  
- To explore the presence and distribution of proteins related to thyroid, in endometrium and 
Fallopian tubes  
-  To study the influence of T4 on embryo development. 
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7.   MATERIALS  AND  METHODS  
 
7.1   ETHICAL APPROVALS 
 
           Study I was approved by the Regional Ethical Review Board in Stockholm (2009/2:6). 
Study II was approved by the Regional Ethical Board in Stockholm and the Regional Ethical 
Board in Uppsala (2008/046/1 2012/339). The women who donated Fallopian tubes and 
endometrium gave their informed consent before participation. The human embryos were 
donated for research after 5 years limit storage has passed. Both partners of the couples 
involved signed an informed consent form after receiving oral and written information. 
 
7.2   MATERIAL  
 
7.2.1   Serum samples 
 
          Serum levels of TSH in 1298 women up to 12 weeks and 6 days of pregnancy were 
analyzed between 2009 and 2011. The TSH levels in a high-risk group were compared to a 
low risk and a general screenings group (Table 1). The criteria for high-risk group wer based 
on recommendation for screening, in Stockholm, at the time of study. Women with diabetes 
sever cardiovascular diseases and systemic lupus, were not included in this study, since they 
are usually attend to specialist care unites.  
Furthermore serum levels of fT4, TSH and TPO-Ab in women with proven fertility were 
compared to women with unexplained infertility. 
 
7.2.2   Endometrial and Fallopian tube biopsies  
 
        Endometrial biopsies from women with unexplained infertility was compared to 
endometrial biopsies from healthy fertile controls for detection of TRα1, TRβ1, TSH R, 
DIO2 and MCT8 proteins. These samples were obtained during receptive phase (Table 1).  
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Fallopian tube samples were used for analyses of TRα1, TRβ1, TSH R and DIO2. These 
samples were collected from healthy volunteers with proven fertility attending the hospital 
for laparoscopic tubal sterilization or hysterectomy due to myoma. Six samples were taken 
during the follicular phase, cycle day (cd) 1-13, and seven samples were during the luteal 
phase, cd 14-28 (Table 1).  
Endometrial biopsies were used for detection of MCT8 protein in fertile women (n = 28) 
with an average age 35.9 years and the mean BMI of 24.9. These samples were taken during 
follicular phase on cycle days 1 to 13 (n = 9), early luteal phase on cycle days 14 to 18 (n = 
6), mid luteal phase on cycle days 19 to 22 (n = 6) and late luteal phase on cycle day 23 to 28 
(n = 7).  
Table  1.  Characteristics  of  study  participants  included  in  study.  Data  is  presented  as  median  and  
median  -­  range.  Statistics  according  to  Chi  Square,  Mann-­Whitney  rank  sum  test  and  Kruskal  Wallis  
test.  Statistically  significance  value  was  set  at  p  ≤  0.05.  
 
TSH samples Low risk (n=511) High risk (n=88) General (n=699) P-Value 
Age 
BMI 
33 (17-49) 
23 (17-46) 
35 (22-44) 
23 (15-34) 
30 (16-50) 
- 
0.001 
0.718 
Serum samples Fertile (n=67) Infertile (n=147)   
Age 
BMI 
36 (24 - 44) 
23.3 (18.4 – 32.8) 
34 (22 – 40) 
22.8 (17.1 – 37.4) 
 
 
0.899 
0.152 
Endometrial samples  Fertile (n = 29) Infertile  (n = 19)   
Age 
BMI 
36 (25 – 41) 
24.5 (22.5 – 27.4) 
35 (31 – 39) 
22.3 (18.4 - 29.4) 
 
 
0.208 
0.475 
Tubal samples  Follicular phase (n=6) Luteal phase (n=7)   
Age 
BMI 
40 (37 – 44) 
28.5 (23.1 – 36.8) 
41 (39 – 46) 
28.2 (21.4 – 35.5) 
 
 
0,295 
 0.413 
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7.2.3   Human embryos 
 
        Human embryos were used to explore addition of T4 (n = 38) compared to control 
embryos (n = 36) on early blastocyst development. The blastocysts were scored according to 
Gardner and Schoolcraft [65]. Each embryo is assigned a quality score based on blastocyst 
development, quality of inner cell mass and quality of trophectoderm.  
 
7.3   METHODS  
 
7.3.1   ELISA 
 
        Serum samples from pregnant women were collected at the first visit at maternal care 
units and TSH in serum was analyzed according to clinical routine at Karolinska University 
Hospital in either Solna or Huddinge.  
All blood samples in fertile and infertile women were collected at the clinic or at the research 
laboratory and were stored at -20°C. All samples were analyzed at the same times by use of 
ELISA according to instruction from manufacturer. Enzyme linked immunosorbent assay 
(ELISA) were used for analyzing of fT4, TSH and TPO-Ab. 
  
7.3.2   Embryo Culture 
 
        Frozen-thawed embryos of high quality embryos were used. The embryos were 
randomly allocated to be cultured in standard media with T4 added to a final concentration of 
20 pmole/L (n=38) or in standard culture media (n= 36) until day 6 and thereafter blastocyst 
formation was determined according to Gardener. 
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7.3.3   Endometrial and Fallopian tube samples 
 
        The endometrial biopsies were obtained using pipelle aspiration while Fallopian tube 
samples were obtained during surgery. For determination of the day of cycle, either the LH 
surge or cycle day was used. The tissue samples were fixed in 4 % formaldehyde and then 
stored in 70 % ethanol until embedding.  
7.3.3.1   Immunohistochemistry  
 
        Immunohistochemistry (IHC) was used for detection and location of thyroid related 
proteins in tissue from endometrium and Fallopian tube. Immunohistochemistry is a method 
used primarily to detect the distribution of proteins in a tissue. In brief, a specific primary 
antibody interacts with an antigen in the tissue (Table 3). For detection a biotinylated 
secondary antibody conjugated and thereafter visualized by enzymatic activation of a 
chromogenic substrate was used.  
Table  3.  Antibodies  used  in  immunohistochemistry.  
 
Antibody Receptor Concentration  
Polyclonal Rabbit IgG TRα1 5 µg/ml 
Polyclonal mouse IgG  TRα2 5 µg/ml 
Polyclonal Rabbit IgG  TRβ1 3 µg/ml 
Monoclonal mouse IgG  TSH R 2.5 µg/ml 
Polyclonal Rabbit IgG DIO2 50 µg/ml 
Polyclonal Rabbit IgG MCT8 50 µg/ml 
For evaluation of immunohistochemistry, two observers evaluated the staining intensity of 
each sample. Staining intensity and the number of stained cells were graded according to the 
following: 0 = no staining, + = faint staining, ++ = moderate staining, and +++ = strong 
staining. 
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7.3.4   Statistical  Analysis  
 
        For descriptive statistics, independent t-test or Mann-Whitney Rank Sum Test were 
used. For comparisons between three or more groups, chi-square test was used in the first 
study and Kruskal-Wallis test followed by Dunn's test was used in the second study. For the 
number of median and good quality embryos, Fischer’s exact test was used. All statistical 
differences with p values ≤ 0.05 were considered statistically significant. 
  
8.     RESULTS    
 
          The incidence of subclinical hypothyroidism and hypothyroidism was almost the same, 
(almost 10), in all three groups regardless of TSH levels ≥ 2.0 mU/L or ≥ 2.5 mU/L in early 
pregnancy (Figure 5).  
 
 
Figure  5.  Flow  diagram  of  study  population  of  early  pregnant  women  and  the  incidences  of  subclinical  
hypothyroidism  and  hypothyroidism    
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Hypothyroid women on LT4 treatment prior to pregnancy (n= 77) had in 50.6 % of cases a 
TSH level ≥ 2.0 mU/L and in 36.4 % of cases a TSH levels ≥ 2.5 mU/L. 
During this study all women with subclinical hypothyroidism were treated with LT4 and 
monitored with control of fT4, TSH during pregnancy with a goal of treatment at TSH level < 
2.0 mU/L.  
 
8.1.1   Serum level of TSH, free T4 and TPO-Ab in fertile and infertile 
women 
 
        The women with unexplained infertility had significantly higher serum level of fT4. 
There were no significant differences in the serum levels of TSH and TPO-Ab between the 
groups (Figure 6). 
    
 
Figure  6.  Serum  levels  of  fT4,  TSH  and  TPO-­Ab  in  study  population:  Serum  levels  of  (a)  fT4  and  (b)  
TSH  and  (c)  TPO-­Ab  in  fertile  control  women  (C)  and  in  women  with  unexplained  infertility  (I).  
Statistics  was  performed  according  to  Mann-­  Whitney  Rank  Sum  Test,  p  <  0.05  was  considered  
statistical  difference  (*).  
 
8.1.2   Thyroid hormone influence on embryo development 
 
 
            The number of good quality embryos, according to Gardner and Schoolcraft’s 
classification, were significantly higher (p = 0.031) in the T4 treated group, 25 (65 %), 
compare to embryo in control group 18 (50 %). (Figure 7) 
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   Figure  7.  Number  of  embryos  that  reached  a  good  quality  blastocysts  in  (C)  Control  group  and  in  (T)  
Treated  with  thyroid  hormone Statistics  according  to  Fischer’s  exact  test  calculated  on  the  percentage  
for  the  number  of  median  and  good  quality  embryos,  p  <  0.05  was  considered  statistical  difference.    
 
 
 
8.1.3    The protein staining of  
8.1.4   R, TRα1, TRβ1, DIO2and MCT8 in the endometrium in infertile 
and fertile controls. 
 
 
             The highest protein staining of TSH R, TRα1 and TRβ1 was identified in the luminal 
epithelium. There was a significant lower protein staining of TRα1 and MCT8 in glandular 
epithelium in endometrium from unexplained infertile women compared to endometrium 
from fertile controls. (Figure 8)  
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Figure  8.  Endometrial  protein  staining  of  TSH  R  (a),  TRα1  (b),  TRβ1  (c),  DIO2  (d)  and  MCT8  (e)   in  
endometrium  from  women  with  unexplained  infertility  compare  to  controls.  The  staining  intensity  was  
generally  higher  in  the  luminal  epithelium  (LE)  followed  by  the  glandular  epithelium  (GE)  and  the  least  
intense   staining   was   seen   in   the   stroma   (St).   Statistical   differences   were   calculated   according   to  
Kruskal-­Wallis  U-­test,  p  <  0.05  was  considered  statistical  difference  (*).  
  
8.1.5   The protein staining of MCT8 in endometrium during the 
menstruation cycle in fertile women  
 
The protein staining of MCT8 showed to be significantly higher in mid luteal phase in 
glandular epithelium in fertile women (Figure 9).  
  
 
Figure  9.  The  protein  staining  of  MCT8   in  the  endometrium  during  the  menstrual  cycle.  The   luminal  
epithelium  (a),  glandular  epithelium  (b)  and  stroma  (c).  The  most  intense  staining  intensity  was  seen  in  
the  mid   luteal  phase  (M)  compared  to  the  follicular  phase  (P),  early  luteal  phase,  (E)  and   late   luteal  
phase   (L).   Statistical   differences   were   calculated   according   to   Kruskal-­Wallis   one-­way   analysis   of  
variance  on  ranks  followed  by  Dunn’s  test.  p  <  0.05  (*)  was  considered  statistical  difference.  
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8.1.6   The protein staining of TSH R, TRα1, TRβ1 and DIO2 in the 
Fallopian tube 
 
        Furthermore we could identify staining of proteins related to thyroid in Fallopian tube. 
The TSH R was identified in the cytoplasm of epithelium and muscle cell in isthmus and 
fimbria and in all three-cell types in the ampulla part of Fallopian tubes. The TSH R, TRα1, 
TRβ1 and DIO2 proteins were identified in the cytoplasm of epithelium, as well as in the 
stromal and vessels in all three part of the Fallopian tube. The highest staining of these 
proteins was identified in the epithelium, p <0.001(Figure 10).  
  
  
  
Figure  10.  The  immune  staining  intensity  of  TSH  R  (a),  TRα1(b),  TRβ1  (c)  and  DIO2  (d)  in  the  three  
compartments  of  Fallopian  tube  from  fertile  women.  The  staining  intensity  of  TSH  R,  TRα1,  TRβ1  and  
DIo2   was   significantly   different   in   all   three   compartments   of   fallopian   tubes;;   Epithelial   cells   (E),  
Vessels  (V),  Stroma  (St).  Statistics  according  to  Kruskal-­Wallis  one-­way  analysis  of  variance  on  ranks  
followed  by  Dunn’s  test,  p  <  0.001  (***)  was  considered  statistical  difference.  
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9.       DISCUSSION  
 
          It is well known that thyroid dysfunction have negative influence on female fertility 
and there is growing evidence of a correlation between untreated thyroid dysfunction during 
pregnancy and adverse pregnancy outcome for the pregnant woman and the growing fetus 
[40, 44, 46, 53, 66]. Even the association between SCH with infertility and adverse pregnancy 
outcomes is discussed, it’s clear that untreated hypothyroidism and hyperthyroidism are 
associated with pregnancy complication. This highlights the importance of proper screening 
model for detection of thyroid dysfunction in early pregnancy. 
Our study showed almost the same incidence of SCH and hypothyroidism (9.6 %-10.2 %) in 
all pregnant women regardless of risk of thyroid disease. This confirms the results of a 
previous study conducted in Uppsala community in Sweden [67], which showed a similar 
incidence of elevated trimester specific TSH in a target screening group (12.1 %), and in an 
unselected screening group (12.6 %). Furthermore, a Cochrane review of different screening 
methods of TSH during early pregnancy showed that the number of women diagnosed and 
subsequently treated for thyroid dysfunction will increase by universal screening [68].  
This study highlights the importance of analyzing TSH as a measure of thyroid function in 
women with hypothyroidism on LT4 treatment prior and early in pregnancy. In our study, in 
50 % of cases the women on LT4 treatment had suboptimal LT4 treatment in early 
pregnancy. This is in agreement with studies by Hallengren et al. in Malmö, Sweden and 
Vadiveloo et al. in Tayside, Scotland, who reported that 30 % of women on LT4 treatment 
had suboptimal treatment [69, 70]. The reason why this is important is that the maternal 
production of thyroxin increases by 30 %–50 % in early pregnancy. Therefore, women with 
known hypothyroidism usually need increased dose of LT4 as soon as pregnancy is 
confirmed. The fetal secretion of thyroid hormone does not start until 18th to 20th weeks of 
pregnancy. Thus, it is of importance to achieve adequate thyroid hormone levels in these 
women during early pregnancy [71].  
There is an ongoing debate about the upper limit of the normal TSH and the benefits of 
thyroxine therapy, in case of SCH, during early pregnancy. The cut-off TSH level (TSH 2.0 
mU/L) was based on clinical guide lines for treatment of LT4 during pregnancy at the time of 
study in Stockholm. In 2017, the previous recommendation for upper limit of serum TSH 
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level of first trimester was specified by the American Thyroid Association from TSH 2.5 
mU/L to 3.5 mlU/L [72]. The Swedish guidelines for treatment of SCH during pregnancy 
now include an upper limit of TSH at 3.5 mU/L during the first trimester and general 
screening during early pregnancy has been recommended (http://online.liebertpub.com/doi/ 
pdfplus/10.1089/thy.2016.0457). However, general screening for thyroid dysfunction has not 
yet been recommended by the American Thyroid Association.  
In the present study, the women with unexplained infertility showed a slightly higher level of 
fT4, reduced protein staining of TRα1 and MCT8. The lower levels of TRα1 in the 
endometrium of infertile women, might explain the required higher levels of fT4. Thyroid 
hormone supplementation in rat has induced higher expression of TRα and TRβ in the uterus 
[73].  
In addition, lower levels of MCT8 were found in both endometrial glandular epithelial cells 
and stromal cells from infertile women compared to fertile control women. The action of 
thyroid hormone at the target cell level is dependent on the ability of T4 and T3 transport into 
the cells, local enzymatic activation of fT4 and co-regulators. The reduced levels of TRα1 on 
the endometrial cell in women with infertility might be the results of low levels of thyroid 
hormone in these cells, due to reduced levels of MCT8.  
Furthermore, the present study showed higher levels of MCT8 protein during the mid-luteal 
phase, which indicates the ability to transport TH into the epithelial cells might be important 
for normal receptivity of the endometrium.  
The presence of TH in culture media had a positive impact on embryo development in vitro. 
Furthermore, the presences of different proteins belong to direct action of thyroid system on 
Fallopian tubes, implicating a physiological role in regulating early embryo development. 
In the present study it was demonstrated that by adding T4 to culture media, embryo 
development was enhanced. Previous studies in bovine and mouse have shown the same 
improvement of thyroid treatment for early embryo development. Furthermore, in a 
systematic review of LT4 treatment in women undergoing IVF/ICSI was shown an 
improvement of take-home baby rate in this group. Therefore, LT4 supplementation for 
women with SCH and/or thyroid autoimmunity who are undergoing fertility treatment is 
recommended.  
One limitation of this study was that TSH and fT4 levels in serum were not obtained during 
sampling of endometrium.  
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In conclusion, adequate diagnosis and treatment of thyroid disease in women that are either 
pregnant or trying to become pregnant is of importance for successful pregnancy outcome. 
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10.   CONCLUSIONS  
 
• High-risk screening is not optimal to determine which women are at risk of 
thyroid disease during early pregnancy.  
• Early adjustments of thyroid hormone treatment is important in case of known 
hypothyroidism in women during early pregnancy. 
•                    Thyroid systems in women with infertility (fT4 level, TRα1and MCT8) seem to 
be imbalanced.  
• The presence of TRα1, TRβ1 and TSH R, and the thyroid hormone related 
proteins, MCT8 and D2 in the Fallopian tubes in combination with improvement of embryo 
development by T4 treatment show that thyroid hormones are important for early embryo 
development.  
• Supplementation of thyroid hormone in preimplantation embryo culture seem 
to improve embryo development and might thereby increase success rate after fertility 
treatment. 
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